NASDAQ:KZR - Kezar Life Sciences Stock Price, Forecast & News

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

Kezar Life Sciences Inc (NASDAQ:KZR) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.51) by $0.03. View Kezar Life Sciences' Earnings History.

Kezar Life Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Kezar Life Sciences.

3 brokers have issued 12-month target prices for Kezar Life Sciences' stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Kezar Life Sciences' share price to reach $15.00 in the next year. This suggests a possible upside of 358.7% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

News articles about KZR stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Kezar Life Sciences.

Some companies that are related to Kezar Life Sciences include BIOFRONTERA AG/ADR (BFRA), Concert Pharmaceuticals (CNCE), Seres Therapeutics (MCRB), Hookipa Pharma (HOOK), MEI Pharma (MEIP), Syndax Pharmaceuticals (SNDX), Theratechnologies (THERF), Affimed (AFMD), Theratechnologies (THTX), Advanz Pharma (CXRXF), Cerecor (CERC), Aeglea Bio Therapeutics (AGLE), Ocular Therapeutix (OCUL), Tyme Technologies (TYME) and LifeVantage (LFVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include Zoetis (ZTS), ACADIA Pharmaceuticals (ACAD), Agile Therapeutics (AGRX), Align Technology (ALGN), BIOLINERX LTD/S (BLRX), Audentes Therapeutics (BOLD), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Gilead Sciences (GILD).

(KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KZR stock can currently be purchased for approximately $3.27.

Kezar Life Sciences has a market capitalization of $62.59 million. The company earns $-23,170,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. Kezar Life Sciences employs 24 workers across the globe.View Additional Information About Kezar Life Sciences.

The official website for Kezar Life Sciences is http://www.kezarlifesciences.com/.

Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-822-5600 or via email at [email protected]